Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $66.13 Average Target Price from Brokerages

Janux Therapeutics, Inc. (NASDAQ:JANX) has been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $66.13.

A number of equities analysts recently weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $100.00 price target on shares of Janux Therapeutics in a report on Monday. Stifel Nicolaus assumed coverage on shares of Janux Therapeutics in a report on Friday, September 6th. They issued a “buy” rating and a $70.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $63.00 price target on shares of Janux Therapeutics in a report on Monday, August 19th. Wedbush reissued an “outperform” rating and issued a $74.00 price target on shares of Janux Therapeutics in a report on Thursday, August 8th. Finally, Scotiabank cut their price target on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a report on Friday, August 9th.

Janux Therapeutics Price Performance

JANX opened at $49.89 on Thursday. The company has a market capitalization of $2.59 billion, a price-to-earnings ratio of -40.89 and a beta of 3.57. The firm’s fifty day moving average price is $42.99 and its two-hundred day moving average price is $44.15. Janux Therapeutics has a 1 year low of $5.65 and a 1 year high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.20. The firm had revenue of $8.90 million for the quarter, compared to the consensus estimate of $0.77 million. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. Janux Therapeutics’s quarterly revenue was up 709.1% compared to the same quarter last year. As a group, equities analysts anticipate that Janux Therapeutics will post -1.18 EPS for the current year.

Insider Activity

In related news, major shareholder Ventures Xi L.P. Avalon sold 158,031 shares of Janux Therapeutics stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $47.00, for a total value of $7,427,457.00. Following the completion of the sale, the insider now directly owns 2,959,175 shares in the company, valued at approximately $139,081,225. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders sold 268,578 shares of company stock valued at $12,071,151. 35.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Janux Therapeutics

Several large investors have recently bought and sold shares of the business. Summit Securities Group LLC purchased a new position in Janux Therapeutics in the second quarter worth about $29,000. Amalgamated Bank boosted its position in Janux Therapeutics by 61.1% in the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after purchasing an additional 368 shares during the last quarter. Plato Investment Management Ltd purchased a new position in Janux Therapeutics in the second quarter worth about $42,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Janux Therapeutics in the second quarter worth about $151,000. Finally, AQR Capital Management LLC purchased a new position in Janux Therapeutics in the second quarter worth about $215,000. 75.39% of the stock is currently owned by institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.